MedTrace Logo

Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors

NCT07292038 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-01-14

No results posted yet for this study

Summary

This study is to assess the MTD and PK of NM6603 in adult patients with advanced solid tumors.

Conditions

Interventions

DRUG

NM6603

NM6603 is an orally administered investigational small-molecule drug evaluated in this dose-escalation study in patients with advanced solid tumors.

Sponsors & Collaborators

  • NucMito Pharmaceuticals Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-18
Primary Completion
2026-11-30
Completion
2026-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07292038 on ClinicalTrials.gov